Vaxcyte, Inc. Common Stock
PCVXStock
$56.04+60.83%52W
Market Cap$8.08B
P/E—
Div yield—
Beta1.21
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)13.73%
Price vs S&P 500 (4W)14.47%
VGM Score56.48
Market Capitalization$8.08B
Earnings Surprise History
Q1 26-2.30est. -1.79
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PCVXVaxcyte, Inc. Common Stock | — | — | C | $56.04 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Vaxcyte is a clinical-stage biopharmaceutical company developing novel vaccines against bacterial infections, including pneumococcal disease, Group A Streptococcus, and Shigella. The company leverages its proprietary XpressCF cell-free protein synthesis platform to design advanced conjugate and protein vaccine candidates for both adult and pediatric populations. Its pipeline includes multiple vaccine programs at various development stages targeting significant public health needs.